First Patient Dosed in CANbridge’s CAN-008 Phase I/II Trial in Newly-diagnosed Glioblastoma Multiforme in Taiwan First CANbridge Clinical Trial

Sep 26, 2016

CANbridge Signs Agreement with Boehringer Ingelheim to Manufacture Inhibitory Antibody,CAN-017,for Esophageal Squamous Cell Cancer

Aug 11, 2016

CANbridge’s CAN-008 Approved for Phase I/II Trial in Newly-Diagnosed Glioblastoma Multiforme in Taiwan

Jul 26, 2016

CANbridge Appoints Dr. Huai Zhong Hu as Vice President of Preclinical Development

Jul 05, 2016

CANbridge Life Sciences ltd. Elected to be a Member of Phirda

Jun 03, 2016

James Xue, Founder and CEO of CANbridge, Present at 2016 Boston CEO Conference

May 29, 2016

CANbridge Submits Investigational New Drug Application to Taiwan Food and Drug Administration for CAN-008 Phase I/II Trial in Glioblastoma Selects WuXi Biologics to Manufacture CAN-008 for the China Market

Apr 07, 2016

AVEO and CANbridge Life Sciences Announce Exclusive Licensing Agreement for AV-203 Outside of North America

Mar 22, 2016

CANbridge Completes Chinese Glioblastoma Biomarker Study for Lead Candidate, CAN008 Plans to Initiate Phase I/II Trial in Taiwan in 2016

Jan 11, 2016